Thioridazine Interactions

CYP2D6 substrate with narrow therapeutic index. Avoid co-administration with abiraterone.

Source: NLP:abiraterone

CYP2D6 substrate with narrow therapeutic index. Avoid co-administration with abiraterone acetate.

Source: NLP:abiraterone acetate

Do not use with drugs that both prolong QT interval and are metabolized by CYP2D6.

Source: NLP:dextromethorphan hydrobromide and quinidine sulfate

Do not use fluoxetine with thioridazine due to QT interval prolongation risk.

Source: NLP:fluoxetine

Do not use fluoxetine with thioridazine due to QT prolongation risk.

Source: NLP:fluoxetine hydrochloride

Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant use.

Source: NLP:macimorelin acetate

Do not use olanzapine and fluoxetine capsules in combination with thioridazine.

Source: NLP:olanzapine and fluoxetine

Increased plasma concentrations may increase risk of QTc prolongation and ventricular arrhythmias. Paroxetine is contraindicated in patients taking thioridazine.

Source: NLP:paroxetine

Increased plasma concentrations of thioridazine may increase the risk of QTc prolongation and ventricular arrhythmias.

Source: NLP:paroxetine hydrochloride

Concomitant use is contraindicated; see contraindications and warnings sections.

Source: NLP:paroxetine hydrochloride hemihydrate

Increased plasma concentrations associated with serious and life-threatening QT prolongation and Torsades de Pointes.

Source: NLP:rolapitant

Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinson's disease.

Source: NLP:amantadine hydrochloride

Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly with tetrabenazine.

Source: NLP:tetrabenazine

Coadministration has been reported to worsen tremor in elderly patients with Parkinson's disease.

Source: NLP:amantadine

CYP2D6 substrate antipsychotic. Bupropion inhibits CYP2D6, increasing thioridazine exposure. Dose reduction may be necessary.

Source: NLP:bupropion hcl er (xl)

CYP2D6-metabolized antipsychotic. Bupropion inhibits CYP2D6 and can increase thioridazine concentrations. Consider dose reduction.

Source: NLP:bupropion hydrochloride

Mixing carbamazepine suspension with liquid thioridazine results in formation of an orange rubbery precipitate. Should not be administered simultaneously.

Source: NLP:carbamazepine

Darifenacin may increase thioridazine exposure as it is metabolized by CYP2D6 with narrow therapeutic window. Caution should be taken when used concomitantly.

Source: NLP:darifenacin

Caution when used concomitantly; darifenacin may increase exposure of thioridazine, a CYP2D6 substrate with narrow therapeutic window.

Source: NLP:darifenacin hydrobromide

Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.

Source: NLP:metoprolol

Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.

Source: NLP:metoprolol tartrate

Lethargy and somnolence have been reported following doses of naltrexone hydrochloride when used concomitantly with thioridazine.

Source: NLP:naltrexone hydrochloride

Pindolol increases serum thioridazine levels; pindolol levels may also be increased with coadministration. Monitor therapy.

Source: NLP:pindolol

Co-administration produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours. Pharmacodynamic interaction with no alteration of either drug's pharmacokinetics.

Source: NLP:zaleplon